Sarepta Therapeutics, Inc. - FORM 10-K - EX-10.12 - AMENDMENT NO.2 TO EMPLOYMENT AGREEMENT WITH J. DAVID BOYLE II - March 14, 2011

Attached files

file filename
10-K - FORM 10-K - Sarepta Therapeutics, Inc.d10k.htm
EX-3.4 - AMENDED AND RESTATED BYLAWS OF AVI BIOPHARMA - Sarepta Therapeutics, Inc.dex34.htm
EX-4.1 - FORM OF SPECIMAN CERTIFICATE FOR COMMON STOCK - Sarepta Therapeutics, Inc.dex41.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Sarepta Therapeutics, Inc.dex231.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - Sarepta Therapeutics, Inc.dex312.htm
EX-10.6 - AMENDMENT NO. 2 TO EMPLOYMENT WITH PATRICK IVERSEN, PH.D. - Sarepta Therapeutics, Inc.dex106.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - Sarepta Therapeutics, Inc.dex321.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - Sarepta Therapeutics, Inc.dex322.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - Sarepta Therapeutics, Inc.dex311.htm
EX-10.5 - AMENDMENT TO EMPLOYMENT AGREEMENT WITH PATRICK IVERSEN PH.D. - Sarepta Therapeutics, Inc.dex105.htm
EX-10.2 - AMENDMENT TO EMPLOYMENT AGREEMENT WITH DWIGHT WELLER - Sarepta Therapeutics, Inc.dex102.htm
EX-10.3 - AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT WITH DWIGHT WELLER - Sarepta Therapeutics, Inc.dex103.htm
EX-10.15 - EMPLOYMENT AGREEMENT BETWEEN AVI BIOPHARMA AND PAUL MEDEIROS - Sarepta Therapeutics, Inc.dex1015.htm
EX-10.10 - EMPLOYMENT AGREEMENT BETWEEN AVI BIOPHARMA AND DAVID BOYLE II - Sarepta Therapeutics, Inc.dex1010.htm
EX-10.53 - LEASE EXTENSION AND MODIFICATION AGREEMENT - Sarepta Therapeutics, Inc.dex1053.htm
EX-10.11 - AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT BETWEEN AVI BIOPHARMA & J.DAVID BOYLE II - Sarepta Therapeutics, Inc.dex1011.htm
EX-10.17 - EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN AVI BIOPHARMA & CHRISTOPHER GERABEDIAN - Sarepta Therapeutics, Inc.dex1017.htm
EX-10.36 - EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN UNIVERSITY OF WESTERN AUSTRALIA & AVI - Sarepta Therapeutics, Inc.dex1036.htm
EX-10.18 - OFFER LETTER BETWEEN AVI BIOPHARMA, INC. AND GRAHAM JOHNSON B.SC.,PH.D. - Sarepta Therapeutics, Inc.dex1018.htm
EX-10.57 - LEASE BY AND BETWEEN S/I NORTH CREEK VII LLC AND AVI BIOPHARMA - Sarepta Therapeutics, Inc.dex1057.htm
EX-10.16 - AMENDMENT TO EMPLOYMENT AGREEMENT WITH PAUL MEDEIROS - Sarepta Therapeutics, Inc.dex1016.htm
EX-10.14 - AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT WITH STEPHEN BEVAN SHREWSBERRY, M.D. - Sarepta Therapeutics, Inc.dex1014.htm
EX-10.9 - AMENDMENT TO EMPLOYMENT AGREEMENT WITH DR. RYSZARD KOLE - Sarepta Therapeutics, Inc.dex109.htm

Exhibit 10.12

AMENDMENT NO. 2

TO

EMPLOYMENT AGREEMENT

 

 

This Amendment No. 2 to Employment Agreement (the “Amendment”) is entered into effective the day of 3rd day of November, 2009 (the “Effective Date”) by and between AVI BioPharma, Inc., an Oregon corporation (“Company”) and J. David Boyle II (“Employee”).

RECITALS

A. Whereas, Company and Employee are parties to that certain Employment Agreement dated the 24th day of July, 2008, as amended by Amendment No. 1 to Employment Agreement entered into effective the 1st day of August, 2008, copies of which are attached hereto as Exhibit A (the “Employment Agreement”).

B. Whereas, the Company and the Employee desire to add a provision to the Employment Agreement related to Section 280G of the Internal Revenue Code of 1986, as amended.

Now, therefore, in consideration of the representations, warranties and covenants contained herein, the Company and the Employee agree as follows:

AGREEMENT

 

1. Section 23(b)(iv) is hereby added to the Employment Agreement, and shall state in its entirety as follows:

 

  “(iv) As a result of the uncertainty in the application of Section 280G and 4999 of the Code, it is possible that, despite the limitations on parachute payments provided in this Section 23, amounts may be paid or distributed by the Company to or for the benefit of the Employee under this Agreement or otherwise which are treated as excess parachute payments. In the event that any payments received by the Employee are determined by the IRS to be subject to the federal excise tax under Section 4999 of the Code (the “Excise Tax”), the Company shall pay the Employee as promptly as possible following such determination (but in no event later than the end of the Employee’s taxable year in which the Employee remits the related taxes) an additional amount which may be necessary to reimburse the Employee on an after-tax basis for any Excise Tax that may be imposed on such excess parachute payments and for any interest and penalties related to such Excise Tax that may be imposed by the IRS or a court. In addition, the Company shall indemnify and hold the Employee harmless, on an after-tax basis, from and against any and all losses, costs, damages or expenses (including reasonable attorneys’ and accountants fees) arising out of the imposition on Employee of any Excise Tax.”

2. In all other respects, the Employment Agreement shall remain unchanged and in full force and effect.

IN WITNESS WHEREOF, the parties have executed this Amendment effective the date first set forth above.

 

AVI BioPharma, Inc.    
By:   /s/ Leslie Hudson       /s/ J. David Boyle II
Name:   Leslie Hudson, Ph.D.       J. David Boyle II
Title:   Chief Executive Officer      

 

-2-

EXHIBIT A

Employment Agreement and Amendment No. 1 to Employment Agreement

Previously Filed

Stock widget

Investing forum

Sarepta Therapeutics, Inc. Reports

Also read